Clairity CEO Jeff Luber to Present at BIO International Convention 2025, Highlighting FDA-Approved AI Breast Cancer Risk Platform

BOSTON—(BUSINESS WIRE)—Clairity, Inc., a leading innovator in AI-driven human health solutions, announced today that its executive leadership team will be attending the BIO International Convention 2025 in Boston, which runs from June 16-19. CEO Jeff Luber will deliver a company update during the convention. Additionally, the team will hold one-on-one meetings with investors and potential partners to discuss the company's strategic direction, particularly since Clairity received FDA De Novo authorization for its CLAIRITY BREAST platform, now marketed as Allix5. Anyone interested in arranging a meeting should do so via the conference’s meeting portal or by contacting clairity@lavoiehealthscience.com. The BIO International Convention, recognized as the largest and most comprehensive biotechnology event globally, brings together over 20,000 industry leaders from the life sciences sector. About Allix5 (CLAIRITY BREAST) Allix5, formerly known as CLAIRITY BREAST, is an advanced AI risk prediction platform that uses mammography images to forecast the five-year risk of developing breast cancer. The technology employs deep learning algorithms to analyze images at the pixel level, identifying subtle patterns that the human eye might miss. This platform was trained on millions of mammograms and validated across more than 77,000 images from five distinct screening centers, including both hospital-based and stand-alone facilities. These centers serve a diverse patient population, and the validation process relied on comprehensive five-year outcome data. For more information on its indications for use, visit https://clairity.com/clairity-breast/. About Clairity Clairity, Inc. was established in 2020 and is based in Boston, Massachusetts. The company aims to revolutionize healthcare risk assessment through the integration of artificial intelligence and deep learning. Founded by Dr. Connie Lehman and supported by investors such as Santé Ventures, ACE Global Equity, and the Breast Cancer Research Foundation, Clairity's technology can detect minute patterns in routine medical imaging that are imperceptible to human observers. This capability significantly enhances risk prediction, providing clinicians and patients with actionable, personalized insights. The company's mission is to move healthcare from reactive treatment to proactive prevention, with a focus on transforming the standard of care for various health conditions. For more information, visit www.clairity.com or follow the company on LinkedIn. More News from Clairity, Inc. Stay tuned for further announcements and developments from Clairity, Inc. as they continue to push the boundaries of AI in healthcare.